Tag: genomics
-
Trial Begins Testing RNA Therapy for Alcohol Disorder
A clinical trial is underway testing a therapy that silences genes to create reactions in people with alcohol use disorder to help them stop drinking.
-
Off-the-Shelf Stem Cell Company Forms, Gains $72M
A new enterprise developing packaged blood-forming stem cells as therapies for a range of diseases began operations and raised $72 million in venture funds.
-
Gene Therapy Delivery Company Gains $26M in Early Funds
A developer of delivery methods for gene therapies promising greater safety for patients is raising $26 million in its first venture funding round.
-
Animal Genome Biotech Raises $9M in Seed Funds
A company discovering new drugs for a range of diseases based on the genomes of hibernating animals is raising $9 million in seed funds.
-
FDA Okays One-Time HIV Treatment Clinical Trial
A company developing a one-time treatment for HIV infections using the gene-editing technique Crispr says it received FDA clearance to begin a clinical trial.
-
Gene-Edited Treatments in Works for Safer Cancer Therapies
A cancer center and biotechnology enterprise are developing gene-edited therapies working in the gut to reduce adverse effects from cancer immunotherapies.
-
Pharma, Synthetic Bio Companies to Find Antibody Therapies
A pharmaceutical company and developer of synthetic genomic materials are collaborating on discovery of therapeutic antibodies to treat a range of diseases.
-
Small Biz Grant Funds Superbug Therapy Technology
A company designing synthetic viruses that attack antibiotic-resistant bacteria is receiving National Science Foundation funds to advance its work.
-
AI-Analyzed Liquid Biopsy IDs Early Lung Cancer
A blood test analyzed with algorithms is shown to detect more than 90 percent of early-stage lung cancer cases in people at high risk of the disease.
-
CEPI Funding Covid-19 Variant Vaccine
A biotechnology company is advancing a vaccine to protect against disease from SARS-CoV-2 variants, with new support from the organization CEPI.